Organogenesis Holdings Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Organogenesis Holdings Inc. now
Current reporting with the operating signal separated from the noise.
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
The story matters when it changes Organogenesis Holdings Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update
The story matters when it changes Organogenesis Holdings Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Organogenesis Holdings Inc. (ORGO)
The story matters when it changes Organogenesis Holdings Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
Investors are testing whether Organogenesis Holdings Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Organogenesis Holdings Inc. (ORGO): Is It Among the Best NASDAQ Penny Stocks to Invest In Now?
Investors are testing whether Organogenesis Holdings Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.TUESDAY DEADLINE: Organogenesis Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ORGO
The story matters when it changes Organogenesis Holdings Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock
Investors are testing whether Organogenesis Holdings Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2019 Results
The story matters when it changes Organogenesis Holdings Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest ORGO filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Organogenesis Holdings Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
Second quarter
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →